EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”

Lilian van Wagensveld iD, Olivier Colomban iD, Maaike A van der Aa iD, Gilles Freyer iD, Gabe S Sonke iD, Roy F P M Kruitwagen iD, Benoit You iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Lilian van Wagensveld und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands. Hauptthemen laut MEDLINE: CA-125 Antigen, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Neoadjuvant Therapy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: DCS, KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The modeled CA-125 ELIMination rate constant K (KELIM) has been validated as a marker of response to chemotherapy in >12,000 patients with advanced epithelial ovarian carcinoma (EOC) treated in first-line setting enrolled in >12 clinical trials. Patient KELIM is calculable online https://www.biomarker-kinetics.org/presentation. The objective was to investigate the prognostic value of KELIM in a large real-life national cancer registry with non-selected patients. METHODS: We investigated 4,025 EOC patients from the Netherlands Cancer Registry treated with neoadjuvant chemotherapy (NACT) ± followed by interval debulking surgery (IDS). Patient KELIM values were calculated in patients with ≥ 3 CA-125 measurements during NACT. KELIM was standardized with a pre-specified cut-off and scored as unfavorable/favorable (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CA-125 AntigenOvarian NeoplasmsCarcinoma, Ovarian EpithelialNeoadjuvant TherapyCytoreduction Surgical ProceduresHumansFemaleMiddle AgedAgedAdultAntineoplastic Combined Chemotherapy ProtocolsNetherlandsRegistriesPrognosisNeoplasm StagingProgression-Free SurvivalChemotherapy, AdjuvantAged, 80 and overBiomarkers, Tumor

Stichwörter der Autor:innen

Antigen, CA-125KineticsModels, TheoreticalOvarian NeoplasmsPrognosisSurvival

Substanzen

CA-125 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
  • GROW, School for Oncology and Developmental Biology and Reproduction, Maastricht, The Netherlands. l.vanWagensveld@iknl.nl.
  • Faculté de Médecine Lyon-Sud, Université Lyon, Université Claude Bernard Lyon 1, Lyon, France.
  • Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • GROW, School for Oncology and Developmental Biology and Reproduction, Maastricht, The Netherlands.
  • Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands.

ORCID-Profile: Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You

Förderung

  • DCS
  • KWF Kankerbestrijding

Zitieren

APA

van Wagensveld, L., Colomban, O., van der Aa, M. A., Freyer, G., Sonke, G. S., Kruitwagen, R. F. P. M., & You, B. (2024). Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e34

Vancouver

van Wagensveld L, Colomban O, van der Aa MA, Freyer G, Sonke GS, Kruitwagen RFPM, et al. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e34

BibTeX
@article{vanWagensveld2024,
  author = {van Wagensveld, Lilian and Colomban, Olivier and van der Aa, Maaike A and Freyer, Gilles and Sonke, Gabe S and Kruitwagen, Roy F P M and You, Benoit},
  title = {Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e34}
}
Kostenlos starten →